All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
December 2023: COVID-19 treatments for patients who do not require hospitalisation
News
December 2023: COVID-19 treatments for patients who do not require hospitalisation
New formulary guidance
COVID-19 treatments for patients who do not require hospitalisation
New formulary guidance has been published on the treatment pathway and treatment options for patients in primary care with a new infective episode of COVID-19 who do not require hospitalisation. The guidance is based on NICE TA878 and a national interim commissioning policy. Specialist support is provided by the COVID Medicine Delivery Units (CMDUs).
- Click here for the formulary guidance.
- Click here for the clinical referral guidance.
Drug changes
Paxlovid (nirmatrelvir 150mg tablets/ ritonavir 100mg tablets) have been reclassified from red (hospital only) to green (first line) for COVID-19 infection in patients in primary care who do not require hospitalisation.
- Click here for the formulary entry.
Molnupiravir 200mg capsules have been reclassified from red (hospital only) to amber (may be prescribed in primary care on the advice of a specialist) for COVID-19 infection in patients in primary care who do not require hospitalisation.
- See here for the formulary entry.
